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Live Stream
Click this link or copy link to your browser to
view the Mock IRB.
http://stream.nts.wustl.edu/R131029001/
Slides for the Mock IRB follow.
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CNE Disclosures
 Successful Completion: Participants must complete an evaluation form to
receive a certificate of completion
 Contact Hours: 1 contact hour is available to those who meet the successful
completion requirements
 Sponsorship & Commercial Support: This activity has received no
sponsorship or commercial support
 Conflict of Interest: No conflicts of interest were identified
 Non-Endorsement: Accreditation approval refers only to MONAs continuing
education activities and does not imply MONA or ANCC Commission on
Accreditation endorsement of any commercial products
 Off Label Use: There will be no discussion of uses of products other than
what is approved by the FDA.
 Expiration: Contact Hours expire on October 29, 2015
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Titles in Human Subjects Research
• FDA: 21 CFR 50 and 56
• HHS: 45 CFR 46
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Criteria for approval 45 CFR 46.111, 21 CFR 56.111

• Risks to subjects are minimized
• Risks to subjects are reasonable in relation to
anticipated benefits
• Selection of subjects is equitable
• Obtain informed consent
• Document informed consent
• Monitoring plan
• Protect privacy & maintain confidentiality
• Protect vulnerable populations
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Actors and their Role
Principal Investigator (PI)

IRB Chair
IRB Administrative Rep.
IRB Analyst

IRB Coordinator
Physician Scientist (PS)
Other Scientist (OS1)
Other Scientist (OS2)
Non-Scientist (NS)

Suresh Vedantham
Ed Casabar
Michael Leary
Linda VanZandt
Charmin Montgomery
Mitchell Sommers
Michelle Jenkerson
Sarah Fowler-Dixon
Niki Bridges
Narrator, Martha Jones
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Reviewers’ Responsibilities
• All committee members are responsible for
reviewing all agenda items prior to the
meeting so they can discuss and vote on all
items.
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Study Documents sent for IRB Review
and Approval Attachments
Study Materials
•
•
•
•
•
•
•
•
•
•
•
•

Study Protocol
Grant
Investigator’s Brochure
FDA IND approval letter
Adult consent form
Minor assent form
Spanish adult consent form
Spanish minor assent form
Translation certification
Phone scripts
Patient cost diary
Questionnaires

Recruitment Materials
• Facebook advertisement
• Social media discussion
boards used for recruitment
• Study website
• Physician poster
• Subject poster
• Patient brochure
• Physician to physician
recruitment letter
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The purpose of this study
• To determine if Pharmacomechanical CDT (PCDT)
should be routinely used to treat proximal DVT. In
order to do this, they are conducting a
multicenter randomized clinical trial (the Acute
Venous Thrombosis: Thrombus Removal with
Adjunctive Catheter-Directed Thrombolysis
[ATTRACT] Trial) to establish whether PCDT
prevents Post-Thrombotic Syndrome (PTS) and
improves health-related Quality of Life (QOL) with
acceptable safety and costs.
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The Primary Objective
• To determine if initial adjunctive use of PCDT
(using rt-PA) with optimal standard DVT
therapy reduces the occurrence of the PostThrombotic Syndrome during 24 months of
follow-up compared with optimal standard
DVT therapy alone.
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Regulatory Criteria for Approval
•

(1) Risks to subjects are minimized:

– (i) By using procedures which are consistent with sound research
design and which do not unnecessarily expose subjects to risk,
and
– (ii) whenever appropriate, by using procedures already being
performed on the subjects for diagnostic or treatment purposes.

•

(2) Risks to subjects are reasonable in relation to anticipated
benefits, if any, to subjects, and the importance of the
knowledge that may reasonably be expected to result.

– In evaluating risks and benefits, the IRB should consider only
those risks and benefits that may result from the research (as
distinguished from risks and benefits of therapies subjects would
receive even if not participating in the research).
– The IRB should not consider possible long-range effects of
applying knowledge gained in the research (for example, the
possible effects of the research on public policy) as among those
research risks that fall within the purview of its responsibility
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Children: Research must fit into one of the following categories
•

45 CFR 404; 21 CFR 50.51- Research not involving greater than minimal

•

45 CFR 405; 21 CFR 50.52- Research involving greater than minimal risk but
presenting the prospect of direct benefit to the individual subjects.

risk.
– Minimal Risk means that the probability and magnitude of harm
or discomfort anticipated in the research are not greater in and
of themselves than those ordinarily encountered in daily life or
during the performance of routine physical or psychological
examinations or tests.
– Adequate provisions are made for soliciting the assent of the
children and permission of their parents or guardians

– (a) The risk is justified by the anticipated benefit to the subjects;
– (b) The relation of the anticipated benefit to the risk is at least as
favorable to the subjects as that presented by available
alternative approaches; and
– (c) Adequate provisions are made for soliciting the assent of the
children and permission of their parents or guardians
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Children: Research must fit into one of the following categories
•

45 CFR 406; 21 CFR 50.53- Research involving greater than minimal

risk and no prospect of direct benefit to individual subjects,
but likely to yield generalizable knowledge about the
subject's disorder or condition.
– (a) The risk represents a minor increase over minimal risk;
– (b) The intervention or procedure presents experiences to
subjects that are reasonably commensurate with those
inherent in their actual or expected medical, dental,
psychological, social, or educational situations;
– (c) The intervention or procedure is likely to yield
generalizable knowledge about the subjects' disorder or
condition which is of vital importance for the
understanding or amelioration of the subjects' disorder or
condition; and
– (d) Adequate provisions are made for soliciting assent of
the children and permission of their parents or guardians
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Children: Research must fit into one of the following categories
• 45 CFR 407; 21 CFR 50.54- Research not otherwise approvable

which presents an opportunity to understand, prevent, or
alleviate a serious problem affecting the health or welfare of
children
– Research in this category must be reviewed by the IRB
which determines that it does not fall into one of the
previous categories
– The study with the IRB findings is then submitted to the
DHHS Secretary/FDA Commissioner for review by a panel
of experts and sent out for public review and comment
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Component analysis
Intervention

Risk (min, >
min, minor
increase over
min)

If risk not
minimal, is
there PDB?

Patient
demographics

Minimal

Medical History

If PDB,
identify
benefit.

Approval
category

Parent
signs

N/A

404

1

Minimal

N/A

404

1

Physical Exam

Minimal

N/A

404

1

Review of diagnosis
of qualifying DVT
episode

Minimal

N/A

404

1

Lab assessment

Minimal

N/A

404

1
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Component analysis: Pre-Screen
Intervention

Risk (min, >
min, minor
increase over
min)

If risk not If PDB,
minimal, is identify
there
benefit.
PDB?

Approval
category

Parent
signs

Questionnaires

Minimal

N/A

404

1

Calf
circumference

Minimal

N/A

404

1

Villalta PTS scale Minimal

N/A

404

1

Venus duplex
ultrasound

Minimal

N/A

404

1

Review of
School or
Employment
history

Minimal

N/A

404

1
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Component analysis: Study Procedures
Intervention

Risk (min, >
If risk not
min, minor
minimal, is
increase over there PDB?
min)

If PDB,
identify
benefit.

Approval
category

Parent
signs

Standard Care

> Minimal

Yes

Use of SOC
drugs to
dissolve clots

405

1

PCDT Procedure
with
investigational
TPA

> Minimal

Yes

Delivery in to
clot to
dissolve it
faster/better

405

1
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Final Risks to Minors Based on Component Analysis
Risk Rating

Requirements

404; 51
Minimal

One parent’s consent
(One or two may be required by IRB)

405; 52
> Minimal, Direct benefit

One

406; 53
> Minimal, No direct benefit

Both

parent’s consent
(One or two may be required by IRB)
Risk justified by anticipated direct benefit
Benefit approximate to alternatives’ benefit
parents’ consent
 Minor risk over minimal


Children must have disease/condition under study

No

407; 54
Not otherwise approvable

direct benefit

Both

parents’ consent
Generalizeable knowledge
Additional approval from DHHS/FDA
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Criteria for approval of Research
• (4) Informed consent will be sought from each
prospective subject or the subject's legally
authorized representative, in accordance with,
and to the extent required by §46.116.
• (5) Informed consent will be appropriately
documented, in accordance with, and to the
extent required by §46.117.
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Criteria for approval 45 CFR 46.111, 21 CFR 56.111

• (3) Selection of subjects is equitable. In
making this assessment the IRB should take
into account the purposes of the research and
the setting in which the research will be
conducted and should be particularly
cognizant of the special problems of research
involving vulnerable populations, such as
children, prisoners, pregnant women, mentally
disabled persons, or economically or
educationally disadvantaged persons.
20

Criteria for approval of Research
• (6) When appropriate, the research plan
makes adequate provision for monitoring the
data collected to ensure the safety of subjects.
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Criteria for approval of Research
• (7) Adequate provisions to protect the privacy
of subjects and to maintain the confidentiality
of data:
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Privacy and Confidentiality Definitions
• Privacy: The freedom of the individual to pick
and choose for him/herself the time and
circumstances under which, and to the extent
to which his/her attitudes, beliefs, behavior
and opinions are to be shared with or withheld
from others. (Levine, p 163)
• Confidentiality: Mode of management of
private information. (Levine, p. 163)
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Criteria for approval of Research
• (7) (b) When some or all of the subjects are
likely to be vulnerable to coercion or undue
influence, such as children, prisoners,
pregnant women, mentally disabled persons,
or economically or educationally
disadvantaged persons, additional safeguards
have been included in the study to protect the
rights and welfare of these subjects.
24

Do you have a blood clot in your leg (DVT)?
In this National Institutes of Health sponsored study, all patients will receive blood-thinning drugs, the standard treatment
for blood clots. In addition, half of all study patients will be chosen to have their clot dissolved using a new treatment that a
doctor will inject directly into the clotted vein through a specifically –designed drug delivery catheter. The other half of the
patients will receive standard medical care.

Consider joining the ATTRACT study.
All patients will be followed for two years by a specialized team of doctors and nurses to determine if the new clotbusting treatment (TPA) helped prevent long-term complications such as pain, swelling, or skin ulcers (open sores) of
the leg.
Eligible participants must be between the ages of 16 and 75.

Each person will be paid $1000.
Please call.
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Sponsor-Investigator Responsibility
• 21 CFR 312.50 Subpart D--Responsibilities of Sponsors and
Investigators
• FDA IND Application
• http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Ho
wDrugsareDevelopedandApproved/ApprovalApplications/Inve
stigationalNewDrugINDApplication/default.htm
• WU Investigational Drug/Device Accountability
http://research.wustl.edu/PoliciesGuidelines/Pages/IDDA.aspx
• WU IND Awareness Training for Sponsor-Investigators
– Contact HRPO at 314-633-7400
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Coordinating Center or Lead Site should:
Have written agreements with their sites
Ensure IRB approvals are obtained at all sites
Ensure proper training and qualifications
Should develop standard operating procedures
Ensure monitoring for all sites
Collect all adverse events study-wide for data
safety monitoring
• Have regular communications with all sites
•
•
•
•
•
•
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Final Determinations
• Prescriptive Changes to the consent and myIRB application,
and the recruitment advertisement
• Adults: Greater than Minimal Risk
• Minors: Both 45 CFR 404 and 405; 21 CFR 50.51 and 50.52
– One parent signature
– Assent process is appropriate with the prescriptive change to allow the
child to discuss the study privately with the research team

• Continuing review in 1 year
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Thank you
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